News & Events about Janux Therapeutics Inc.
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today...
Market News Video
3 months ago
In trading on Thursday, shares of Janux Therapeutics Inc (JANX) crossed above their 200 day moving average of 13.95, changing hands as high as 14.07 per share. Janux Therapeutics Inc shares are currently trading down about 0.1% on the day...
Business Wire
3 months ago
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today...
Business Wire
4 months ago
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the...
Market News Video
4 months ago
In trading on Wednesday, shares of Janux Therapeutics Inc (JANX) crossed above their 200 day moving average of 14.41, changing hands as high as 15.08 per share. Janux Therapeutics Inc shares are currently trading up about 6.7% on the day...